Something quietly extraordinary happened this year
For most of medicine's history, we have been very good at one thing: managing.
We manage blood sugar. We manage pain crises. We manage tremor. We replace what a failing organ used to do with a drug, a device, or a needle, every day, for the rest of a person's life. It is honourable work and it has added decades to human lifespan. But it is management, not repair.
In March 2026, that changed in a small but permanent way. On a single day, one regulator approved two medicines that are not molecules at all. They are living cells, grown in a laboratory from reprogrammed human stem cells, one injected into the brain, one laid onto a failing heart, doing jobs that the patients' own cells had stopped doing. [1]
They are the first therapies of their kind ever approved anywhere in the world. And they are not alone.
This is a genuinely good news story, and it is worth telling properly, with the actual numbers, the actual dates, and the actual limits. Here are four of them.
Watch: a short explainer on the shift from managing disease to repairing it is on our Instagram.
1. Parkinson's disease: the world's first approved iPS cell therapy
The number: 44.7%, the measured increase in the brain's own dopamine production.
Transplanted dopaminergic progenitors integrating with existing neural tissue. In the Kyoto trial, PET imaging showed the grafts were producing dopamine, not merely surviving.
In Parkinson's disease, the dopamine-producing cells of the midbrain die. Levodopa replaces the missing dopamine chemically, and it works, until it doesn't, and the good hours between doses get shorter.
Researchers at Kyoto University Hospital tried something else. They took induced pluripotent stem cells, ordinary adult cells reprogrammed back into a flexible, embryonic-like state, coaxed them into becoming dopamine-producing neural progenitors, and transplanted them into the brains of seven people with Parkinson's who were no longer responding well to medication.
The results, published in Nature in April 2025, were carefully modest and genuinely encouraging: [2]
No serious adverse events requiring hospitalisation, and no deaths, across all seven participants over 24 months of follow-up. Of 73 adverse events recorded, 72 were mild.
No tumour formation, historically the single biggest fear with pluripotent stem cells. Imaging showed stable grafts with no abnormal overgrowth.
PET imaging showed dopamine synthesis in the putamen rose by 44.7% on average, and by 63.5% in the higher-dose group. The transplanted cells were not just surviving. They were working.
Four of six evaluable patients improved on motor scores while off medication, with an average reduction of 20.4% on the MDS-UPDRS motor scale. Five of six improved while on medication. Four moved down a full Hoehn-Yahr disease stage or more.
On 6 March 2026, Japan's Ministry of Health, Labour and Welfare granted conditional and time-limited approval to AMCHEPRY (raguneprocel), allogeneic iPS cell-derived dopaminergic neural progenitor cells, developed by Sumitomo Pharma from the Kyoto work. [3]
On the very same day, the ministry approved a second one: RiHEART, sheets of iPS cell-derived heart muscle cells developed by Cuorips, grafted onto the hearts of people with severe ischaemic heart failure. [4]
Two products, one day, and the first iPS cell-derived therapies licensed anywhere in the world. Nineteen years after Shinya Yamanaka discovered how to wind an adult cell back to a pluripotent state, the technology has product licences.
The honest caveat: both are conditional, time-limited approvals granted on small trials, and each company must run post-marketing studies to convert them into full ones. Six patients is six patients. But the door is open, and it was never open before.
2. Type 1 diabetes: 83% of people stopped taking insulin
The number: 10 of 12. Insulin-free at one year.
A lab-grown islet responding to glucose. Zimislecel is a single infusion of fully differentiated, glucose-responsive islet cells.
If you want to see what "repair, not manage" looks like in a single statistic, look at this one.
Type 1 diabetes destroys the insulin-producing beta cells in the pancreatic islets. The treatment has been insulin injections since 1922, a hundred and four years of the same fundamental answer.
Vertex Pharmaceuticals took human stem cells and differentiated them into fully mature, glucose-responsive islet cells, then infused them as a single one-time treatment. The therapy is called zimislecel. The results were presented at the American Diabetes Association's 85th Scientific Sessions and published in the New England Journal of Medicine in June 2025: [5]
Outcome | Result |
|---|---|
Achieved insulin independence at 12 months | 10 of 12 (83%) |
Mean reduction in daily insulin | 92% |
Achieved HbA1c below 7% (the ADA target) | 12 of 12 (100%) |
Achieved more than 70% time-in-range | 12 of 12 (100%) |
Free of severe hypoglycaemic events from day 90 | All participants |
Read that again. Ten people who had lived with type 1 diabetes, with the finger pricks, the carbohydrate counting, the 3am hypoglycaemia, the constant low-grade arithmetic of staying alive, stopped needing insulin. Every single participant hit a blood sugar target that most people with type 1 diabetes never reliably reach.
No serious adverse events were attributed to zimislecel itself. Two participants died during the trial: one from cryptococcal meningitis, which the investigators judged related to the immunosuppressive medication that accompanies the treatment, and one from the progression of pre-existing dementia, judged unrelated.
The honest caveats, and they matter: the cells come from a donor line, not from the patient, so recipients take immunosuppressive medication, as with any transplant, and that medication carries risk of its own. Twelve people on the full dose, with a year of follow-up, is a small, early dataset. Zimislecel is still investigational and not yet approved anywhere. It holds FDA RMAT and Fast Track status, EMA PRIME designation, and a UK MHRA Innovation Passport, with regulatory submissions anticipated during 2026. [6]
But the biology is settled. It is possible to grow working islet cells in a factory and give someone their pancreas function back.
3. Sickle cell disease: 29 of 30 patients went a year without a pain crisis
The number: 97%. And this one is already on the shelf.
Casgevy edits the patient’s own blood-forming stem cells so the body resumes making fetal haemoglobin. The gold thread marks the correction.
This is the story that should matter most to African readers, and it is the one with the strongest data behind it.
Sickle cell disease is the most widespread serious genetic disorder on the African continent. The World Health Organization estimates that 7.74 million people worldwide were living with sickle cell disease in 2021, with 515,000 new births that year and nearly 80% of global cases in sub-Saharan Africa. It killed 81,100 children under five in 2021, making it the twelfth leading cause of death in that age group. WHO also notes that the true toll is far higher than cause-specific reporting captures: an estimated 376,000 deaths in 2021 against 34,400 recorded. [7]
The defining experience of the disease is the vaso-occlusive crisis, episodes of severe pain when misshapen red cells block blood vessels. They are unpredictable, they are agonising, and they send people to hospital again and again for a lifetime.
Casgevy (exagamglogene autotemcel) works by collecting the patient's own blood-forming stem cells, using CRISPR-Cas9 to switch a genetic dimmer switch back on so the body resumes making fetal haemoglobin, and returning those edited cells to the patient. It is autologous: your own stem cells, corrected and given back.
The pivotal CLIMB SCD-121 results, published in the New England Journal of Medicine on 24 April 2024: [8]
29 of 30 evaluable patients (97%) went at least 12 consecutive months with no severe vaso-occlusive crisis.
All 30 (100%) remained free of hospitalisation for a severe crisis over that same period.
Forty-four patients were treated in total. Median follow-up: 19.3 months, with the longest approaching four years.
This was a prespecified interim analysis, with long-term follow-up continuing. That is worth noting, because it is the kind of detail that gets dropped when a statistic travels.
Casgevy is not a trial. It is an approved medicine in the United States, the United Kingdom, and the European Union, the first CRISPR-based therapy ever approved anywhere.
The honest caveat, and it is a heavy one: as of early 2026, this therapy remains functionally out of reach across most of Africa, the continent carrying roughly four-fifths of the global disease burden. [9] The science is finished. The access problem is not. That gap is now one of the more important equity questions in global health, and it deserves far more attention than it gets.
4. Paralysis: the frontier, and the story to watch
The numbers: 2 of 4 patients improved in a first-in-human trial. And 80% in the animal work behind the most ambitious programme in the field.
The approach Matricelf is pursuing: neuronal networks grown inside a scaffold made from the patient’s own tissue. No human has yet received one.
Spinal cord injury has been medicine's hardest wall. Once the cord is severed, the signal stops, and nothing we have has reliably restored it.
What has already happened in humans
On 21 July 2026, a team at Keio University in Tokyo led by Professors Hideyuki Okano and Masaya Nakamura published in Nature Medicine the results of the world's first clinical study of iPS cell-derived neural progenitor cells for spinal cord injury. [10]
Four patients, all with complete cervical spinal cord injury, AIS grade A, the most severe classification, treated in the subacute window a few weeks after injury. Each received a single transplant of about two million iPSC-derived neural stem and progenitor cells directly into the injured cord. [11]
No tumour formation and no graft-related serious adverse events, with follow-up extending two to four years. Graft sites remained stable on imaging.
Median motor score improvement of 13 points at 52 weeks (range 10 to 40).
Two of the four patients improved in AIS grade, one from A to C, one from A to D. Half the cohort moved out of the "complete injury" category.
Four patients is a safety trial, not proof of efficacy, and the authors are explicit about that. But cells reprogrammed from a human adult were transplanted into a severed human spinal cord, they did not form tumours over up to four years, and two people in the deepest category of injury moved out of it.
And what is coming
The most ambitious approach in this space belongs to Matricelf, a company spun out of Professor Tal Dvir's Sagol Center for Regenerative Biotechnology at Tel Aviv University.
Their idea is elegantly personal. Take a blood sample from the patient and reprogram those cells into iPS cells. Take a small sample of the patient's own omentum, the fatty apron of tissue in the abdomen, and strip it down to its extracellular matrix, then turn that matrix into a personalised hydrogel. Grow the patient's own stem cells inside their own biological scaffold, guiding them through a process that mimics how the spinal cord forms in an embryo. The result is a three-dimensional implant of living neuronal networks, containing motor neurons, designed to be built entirely from one person's own tissue, so there is nothing for the immune system to reject.
The proof of concept was published in Advanced Science on 7 February 2022. In mice with both acute and chronic spinal cord injury, animals treated with the implant recovered motor function that untreated animals did not. [12] Two things are worth knowing about that work: it was in mice, not people, and the stem cells in it were reprogrammed from omental tissue cells rather than from blood. Blood-derived iPS cells are the plan for the human programme, not something the paper demonstrated.
Matricelf's own rat study, reported in October 2024, found 80% of treated animals showing statistically significant motor improvement on the BBB locomotor scale. [13] That 80% is the figure most often quoted about this technology, and it is worth knowing exactly what it describes. The treated group reached an average BBB score of 9.1 at twelve weeks against 8.5 in untreated controls, a narrow margin on a 21-point scale, in a company-reported study rather than a peer-reviewed one. Untreated animals recover a surprising amount on their own. Which is precisely why the much larger, formally designed efficacy study now running matters more than either headline.
All of this is animal data. No human has yet received a Matricelf implant. Here is exactly where the programme stands: [14]
Date | Milestone |
|---|---|
Mar 2026 | GMP clinical manufacturing collaboration agreed with Sheba Medical Center's Advanced Biotherapy Center [15] |
Jun 2026 | GMP clinical manufacturing activities begin |
15 Jun 2026 | Pivotal preclinical efficacy study begins in 96 animals with chronic injury [16] |
17 Jun 2026 | GLP safety study completed: 248 animals, up to 39 weeks. No treatment-related toxicity, no tumour formation, no migration. All predefined endpoints met. [17] |
9 Jul 2026 | Ethics approval granted, at Loewenstein Rehabilitation Medical Center, to begin collecting blood from patients with complete thoracic spinal cord injury, to generate their iPS cells. The approval states explicitly that it does not authorise implantation or the start of a trial. [18] |
2027 | First human implantation targeted |
That safety result in June is the one that matters most. Two hundred and forty-eight animals, thirty-nine weeks, and no tumours, because uncontrolled growth is the risk that has haunted pluripotent stem cells since the beginning. Clearing it is what makes a first-in-human application credible.
Somewhere in Israel right now, a person with a complete spinal cord injury is having blood drawn so that a piece of their own spinal cord can be grown in a laboratory. That is where we are.
What these four stories have in common
Look across them and a single pattern emerges.
The medicine is a living cell, not a molecule. All four therapies are cells that go in and do a job: make dopamine, sense glucose and release insulin, produce healthy haemoglobin, rebuild a neural circuit.
Increasingly, the cells are yours. Casgevy and Matricelf both use the patient's own cells, corrected or rebuilt. Autologous therapy sidesteps rejection entirely, with no lifetime of immunosuppression.
The intent is one-time, not lifelong. A single infusion. A single transplant. This is a different economic and human proposition from a daily prescription.
Safety is being taken seriously, and it is holding. Across all four programmes, the headline finding is the same: no tumour formation, over follow-up now measured in years. That was the field's existential risk. It is being retired, carefully, one dataset at a time.
The bar is high, and rightly so. The FDA issued more complete response letters, its formal rejections, to cell and gene therapy applications in 2025 than in the year before. Regulators are not waving these through. The approvals that land have earned it.
The part that requires honesty
If you take one thing from this article, take this.
Everything above is real, published in peer-reviewed journals, and either approved by a regulator or advancing through formal clinical trials with ethics oversight and named investigators. That is what legitimate regenerative medicine looks like.
It looks nothing like the clinic offering you a stem cell injection this week for arthritis, autism, MS, long COVID, ageing, or anything else on a long menu, for cash, with no trial registration and no published outcomes. That industry exists worldwide, South Africa included, and it trades on exactly the hope this article describes.
Four questions separate the real from the rest:
Is it registered as a clinical trial, with a number you can look up?
Are the outcomes published in a peer-reviewed journal, with the failures reported alongside the successes?
Is it for one specific, defined condition, rather than a list of unrelated ones?
Has a regulator reviewed it?
Real breakthroughs come with dates, numbers, named investigators, and disclosed limitations. They are announced in Nature and the NEJM, not in a direct message.
Why we find this exciting
Nothing in this article is medical advice or an offer of treatment.
We follow this field closely for a different reason. The logic underneath it is the same logic we practise every day: that measuring a body precisely, understanding it as an individual system, and intervening early beats managing decline late. Regenerative medicine is that idea taken to its furthest conclusion: not slowing the loss, but restoring the function. We have written before about the evidence behind exosome therapy and Muse cells. This is the same field, further along.
Most of what is described above will reach South African patients years after it reaches Tokyo, Boston and Tel Aviv. Some of it, like Casgevy, is already approved elsewhere and still out of reach for the continent that needs it most. That is worth being impatient about.
But the direction of travel is now unmistakable. A generation of clinicians is being trained who will treat "incurable" as a scheduling problem rather than a verdict.
Ten people are living without insulin. Two men who could not move their arms can move them now. Twenty-nine out of thirty went a whole year without a pain crisis. A regulator has approved two medicines grown from reprogrammed human cells.
That all happened in about twenty-four months. It is a very good time to be paying attention.
Medical disclaimer
This article is provided for general information and discussion. It is not medical advice, and it is not an offer of treatment. The therapies described are either approved in specific jurisdictions outside South Africa, or under investigation in registered clinical trials. Anyone considering participation in a clinical trial or seeking treatment abroad should discuss it with their treating physician.